Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

ITM Isotopen Technologien München

ITM Isotopen Technologien München
2004 FOUNDED
PRIVATE STATUS
41-50 EMPLOYEES
PE Growth LATEST DEAL TYPE
4 FINANCING ROUNDS
Description

Developer of novel radiopharmaceuticals and radiomedical devices. The company design and develops novel radiopharmaceuticals and radiomedical devices. The company products are rhenium-SCT for non-invasive skin cancer therapy and ITM rhenium-PTA/PTCA for endovascular brachytherapy.

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Primary Industry
Diagnostic Equipment
Other Industries
Therapeutic Devices
Surgical Devices
Primary Office
  • Lichtenbergstraße 1
  • 85748 Munich
  • Germany

+49 089 0000000000

ITM Isotopen Technologien München Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore ITM Isotopen Technologien München‘s full profile, request access.

Request full access to PitchBook

ITM Isotopen Technologien München Investors

Investor Name Investor Type Holding Participating Rounds Investor Since Board Seat Contact Info

This information is reserved for PitchBook Platform users. To explore ITM Isotopen Technologien München‘s full profile, request access.

Request full access to PitchBook

ITM Isotopen Technologien München Executive Team (5)

Name Title Board
Seat
Contact
Info
Steffen Schuster Chief Executive Officer & Chairman
Thomas Dürre Chief Financial Officer
Mark Harfensteller Ph.D Head, Research & Development & Managing Director of ITG
Richard Henkelmann Ph.D Managing Director
Philip Harris Ph.D Chief Medical Officer

ITM Isotopen Technologien München Board Members (1)

Name Representing Role Since Contact
Info
0000000 00000000 ITM Isotopen Technologien München Chief Executive Officer & Chairman 000 0000